Sequence: CRGDKGPDC
| Experiment Id | EXP001785 |
|---|---|
| Paper | Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC- |
| Peptide | CC9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Free CC9 20 µM (optimal in transfection assays) |
| Rna Concentration | miR-34a 0.15 µM per well (6-well) for qRT-PCR; 0.15 µM FAM-siRNA for uptake assays |
| Mixing Ratio | N/P = 30; CC9 = 20 µM (optimal) added post-complexation |
| Formulation Format | PC/miRNA polyplex with co-administered CC9 (physical combination) |
| Formulation Components | PC/miR-34a polyplex (N/P 30) with free CC9 added after complexation (optimal CC9 20 µM) (PC/miR-34a + CC9) |
| Size Nm | 261.00 |
| Zeta Mv | 16.50 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | PANC-1 (pancreatic cancer) (primary in vitro efficacy); BxPC-3 also tested; 293T as normal control |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional effects: miR-34a upregulation (qRT-PCR), cell cycle arrest, apoptosis, migration inhibition, target gene downregulation |
| Output Value | miR-34a expression substantially increased; apoptosis ~44% (Annexin V/PI) for PC/miR-34a+CC9; target gene mRNA/protein reduced (E2F3, Bcl-2, c-myc, cyclin D1) |
| Output Units | |
| Output Notes | Higher uptake vs PC alone (flow cytometry ~87.5% FAM-positive); competitive inhibition with free RGD reduced uptake for conjugate system. |
| Toxicity Notes | Low cytotoxicity reported (MTT; supporting info). |
| Curation Notes |